Effectiveness of patient-reported outcome-based symptom monitoring after prostate cancer surgery: protocol for a multicenter, randomized controlled trial

前列腺癌手术后基于患者报告结局的症状监测的有效性:一项多中心随机对照试验方案

阅读:2

Abstract

INTRODUCTION: Surgery remains a primary treatment modality for prostate cancer. However, patients often experience a substantial burden of postoperative symptoms, which can significantly delay recovery and negatively impact quality of life. Patient-reported outcome (PRO)-based symptom management has emerged as a promising approach to support patient-centered care. Despite its growing importance, there is a lack of clinical trial evidence evaluating early postoperative symptom management in prostate cancer patients. We propose a multicenter randomized controlled trial to assess the effectiveness of a PRO-based symptom monitoring program with threshold-triggered alerts and clinician responses in promoting postoperative recovery in this population. METHODS: This study will enroll 144 patients with prostate cancer across three hospitals. Participants will be randomly assigned in a 1:1 ratio to either the intervention or control group. The intervention group will receive PRO-based symptom monitoring, whereby specialist clinicians will intervene when scores for target symptoms-pain, fatigue, disturbed sleep, drowsiness, and dry mouth-reach a predefined threshold (score ≥ 4). The control group will receive standard postoperative care without PRO-triggered alerts. Symptom data will be collected using the M.D. Anderson Symptom Inventory at baseline (3 days before surgery) and on postoperative days 1, 2, 3, 5, 7, 14, 28, 42, and 90. The primary outcome-the number of symptom threshold events-will be compared between groups using a t-test. DISCUSSION: This trial aims to investigate early-phase postoperative symptom management in patients undergoing prostate cancer surgery. Specifically, it will evaluate the efficacy and safety of a WeChat-based symptom management system in postoperative care. TRIALS REGISTRATION: This trial was registered in the Chinese Clinical Trial Registry (ChiCTR2400082090) on 20 March 2024, and the registration details are available at https://www.chictr.org.cn/showproj.html?proj=214038.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。